标题
TROP2 (trophoblast cell-surface antigen 2): a drug target for breast cancer
作者
关键词
-
出版物
EXPERT OPINION ON THERAPEUTIC TARGETS
Volume -, Issue -, Pages -
出版商
Informa UK Limited
发表日期
2022-08-13
DOI
10.1080/14728222.2022.2113513
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Cancer statistics, 2022
- (2022) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Sacituzumab govitecan: a new opportunity in the treatment of refractory metastatic triple-negative breast cancer
- (2022) Roberta Maltoni et al. Annals of Translational Medicine
- Primary results from TROPiCS-02: A randomized phase 3 study of sacituzumab govitecan (SG) versus treatment of physician’s choice (TPC) in patients (Pts) with hormone receptor–positive/HER2-negative (HR+/HER2-) advanced breast cancer.
- (2022) Hope S. Rugo et al. JOURNAL OF CLINICAL ONCOLOGY
- TACSTD2 upregulation is an early reaction to lung infection
- (2022) Sára Lenárt et al. Scientific Reports
- CD27 enhances the killing effect of CAR T cells targeting trophoblast cell surface antigen 2 in the treatment of solid tumors
- (2021) Huanpeng Chen et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Trop2 deal heats up antibody–drug conjugate space in cancer
- (2021) Catherine Shaffer NATURE BIOTECHNOLOGY
- Trastuzumab deruxtecan in HER2-positive metastatic breast cancer and beyond
- (2021) Jose Perez et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer
- (2021) Aditya Bardia et al. NEW ENGLAND JOURNAL OF MEDICINE
- Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I/II IMMU-132-01 basket trial
- (2021) A. Bardia et al. ANNALS OF ONCOLOGY
- Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
- (2021) D. Miles et al. ANNALS OF ONCOLOGY
- Recent advances in trophoblast cell‐surface antigen 2 targeted therapy for solid tumors
- (2021) Shutan Liao et al. DRUG DEVELOPMENT RESEARCH
- ImmunoPET of trophoblast cell-surface antigen 2 (Trop-2) expression in pancreatic cancer
- (2021) Weiyu Chen et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Datopotamab deruxtecan (Dato-DXd), a novel TROP2-directed antibody-drug conjugate, demonstrates potent antitumor activity by efficient drug delivery to tumor cells
- (2021) Daisuke Okajima et al. MOLECULAR CANCER THERAPEUTICS
- Current Triple-Negative Breast Cancer Subtypes: Dissecting the Most Aggressive Form of Breast Cancer
- (2021) Miquel Ensenyat-Mendez et al. Frontiers in Oncology
- Does sacituzumab-govitecan act as a conventional antibody drug conjugate (ADC), a prodrug of SN-38 or both?
- (2021) Daniel V. Santi et al. Annals of Translational Medicine
- ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer
- (2021) A. Gennari et al. ANNALS OF ONCOLOGY
- N-glycosylation status of Trop2 impacts its surface density, interaction with claudin-7 and exosomal release
- (2021) Pradnya R. Kamble et al. ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS
- Trop2 Forms a Stable Dimer with Significant Structural Differences within the Membrane-Distal Region as Compared to EpCAM
- (2021) Miha Pavšič INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Treatment landscape of triple-negative breast cancer — expanded options, evolving needs
- (2021) Giampaolo Bianchini et al. Nature Reviews Clinical Oncology
- Bispecific antibody targeting TROP2xCD3 suppresses tumor growth of triple negative breast cancer
- (2021) Huicheng Liu et al. Journal for ImmunoTherapy of Cancer
- Oncogene-mediated metabolic gene signature predicts breast cancer outcome
- (2021) Merve Aslan et al. npj Breast Cancer
- Structural insights into the cis and trans assembly of human trophoblast cell surface antigen 2
- (2021) Meng Sun et al. iScience
- Trop-2 Therapy in Metastatic Triple-Negative Breast Cancer in Italy: Clinical Opportunity and Regulatory Pitfalls
- (2021) Sara Bravaccini et al. Journal of Personalized Medicine
- Trop2 is a driver of metastatic prostate cancer with neuroendocrine phenotype via PARP1
- (2020) En-Chi Hsu et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Small molecules, big impact: 20 years of targeted therapy in oncology
- (2020) Philippe L Bedard et al. LANCET
- Sacituzumab Govitecan: First Approval
- (2020) Yahiya Y. Syed DRUGS
- 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)†
- (2020) F. Cardoso et al. ANNALS OF ONCOLOGY
- Emerging CAR-T Cell Therapy for the Treatment of Triple Negative Breast Cancer
- (2020) Sundee Dees et al. MOLECULAR CANCER THERAPEUTICS
- Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial
- (2020) Javier Cortes et al. LANCET
- The role and molecular mechanism of Trop2 induced epithelial-mesenchymal transition through mediated β-catenin in gastric cancer
- (2019) Wei Zhao et al. Cancer Medicine
- Targeting Trop-2 in solid tumors: future prospects
- (2019) Saif Zaman et al. OncoTargets and Therapy
- Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer
- (2019) Aditya Bardia et al. NEW ENGLAND JOURNAL OF MEDICINE
- Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†
- (2019) F Cardoso et al. ANNALS OF ONCOLOGY
- Trophoblast cell surface antigen 2 (Trop-2) phosphorylation by protein kinase C α/δ (PKCα/δ) enhances cell motility
- (2019) Yugo Mori et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Bispecific antibodies: a mechanistic review of the pipeline
- (2019) Aran F. Labrijn et al. NATURE REVIEWS DRUG DISCOVERY
- Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial
- (2019) Peter Schmid et al. LANCET ONCOLOGY
- Variation of Trop2 on non-small-cell lung cancer and normal cell membranes revealed by super-resolution fluorescence imaging
- (2019) Yilin Fu et al. TALANTA
- Trop-2 plasticity is controlled by epithelial-to-mesenchymal transition
- (2018) Ján Remšík et al. CARCINOGENESIS
- Proportion of U.S. Trends in Breast Cancer Incidence Attributable to Long-term Changes in Risk Factor Distributions
- (2018) Ruth M. Pfeiffer et al. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
- EpCAM homo-oligomerization is not the basis for its role in cell-cell adhesion
- (2018) Aljaž Gaber et al. Scientific Reports
- Sacituzumab for the treatment of triple-negative breast cancer: the poster child of future therapy?
- (2018) Mark L. Zangardi et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- New insights into the mechanisms of epithelial–mesenchymal transition and implications for cancer
- (2018) Anushka Dongre et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- COSMIC: the Catalogue Of Somatic Mutations In Cancer
- (2018) John G Tate et al. NUCLEIC ACIDS RESEARCH
- TROP2 promotes the proliferation and metastasis of glioblastoma cells by activating the JAK2/STAT3 signaling pathway
- (2018) Jianbing Hou et al. ONCOLOGY REPORTS
- Sorafenib for the treatment of breast cancer
- (2017) Giuseppe Bronte et al. EXPERT OPINION ON PHARMACOTHERAPY
- Intracellular trafficking of new anticancer therapeutics: antibody–drug conjugates
- (2017) Muhammad Kalim et al. Drug Design Development and Therapy
- Determination of Cellular Processing Rates for a Trastuzumab-Maytansinoid Antibody-Drug Conjugate (ADC) Highlights Key Parameters for ADC Design
- (2016) Katie F. Maass et al. AAPS Journal
- Cell Surface Antibody Retention Influences In Vivo Antitumor Activity Mediated by Antibody-dependent Cellular Cytotoxicity
- (2016) MASAHIRO IKEDA et al. ANTICANCER RESEARCH
- The St. Gallen surrogate classification for breast cancer subtypes successfully predicts tumor presenting features, nodal involvement, recurrence patterns and disease free survival
- (2016) Ines Vasconcelos et al. BREAST
- DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1
- (2016) Y. Ogitani et al. CLINICAL CANCER RESEARCH
- Trop2 marks transient gastric fetal epithelium and adult regenerating cells after epithelial damage
- (2016) Valeria Fernandez Vallone et al. DEVELOPMENT
- Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease
- (2016) Giampaolo Bianchini et al. Nature Reviews Clinical Oncology
- Palbociclib and Letrozole in Advanced Breast Cancer
- (2016) Richard S. Finn et al. NEW ENGLAND JOURNAL OF MEDICINE
- High expression of TROP2 characterizes different cell subpopulations in androgen-sensitive and androgen-independent prostate cancer cells
- (2016) Jinhan Xie et al. Oncotarget
- Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection
- (2016) Brian D. Lehmann et al. PLoS One
- First-in-Human Trial of a Novel Anti-Trop-2 Antibody-SN-38 Conjugate, Sacituzumab Govitecan, for the Treatment of Diverse Metastatic Solid Tumors
- (2015) A. N. Starodub et al. CLINICAL CANCER RESEARCH
- Trop2: From development to disease
- (2015) Annie R.A. McDougall et al. DEVELOPMENTAL DYNAMICS
- Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC)*
- (2015) David M. Goldenberg et al. Oncotarget
- The cytosolic tail of the tumor marker protein Trop2 - a structural switch triggered by phosphorylation
- (2015) Miha Pavšič et al. Scientific Reports
- US Incidence of Breast Cancer Subtypes Defined by Joint Hormone Receptor and HER2 Status
- (2014) Nadia Howlader et al. JNCI-Journal of the National Cancer Institute
- Trop-2 Is a Determinant of Breast Cancer Survival
- (2014) Federico Ambrogi et al. PLoS One
- TROP2 expression and its correlation with tumor proliferation and angiogenesis in human gliomas
- (2013) Shanglei Ning et al. NEUROLOGICAL SCIENCES
- Overexpression of TROP2 Predicts Poor Prognosis of Patients with Cervical Cancer and Promotes the Proliferation and Invasion of Cervical Cancer Cells by Regulating ERK Signaling Pathway
- (2013) Ting Liu et al. PLoS One
- Biochemical and preliminary X-ray characterization of the tumor-associated calcium signal transducer 2 (Trop2) ectodomain
- (2013) Tilen Vidmar et al. PROTEIN EXPRESSION AND PURIFICATION
- TROP2 is epigenetically inactivated and modulates IGF-1R signalling in lung adenocarcinoma
- (2012) Jau-Chen Lin et al. EMBO Molecular Medicine
- Regulated proteolysis of Trop2 drives epithelial hyperplasia and stem cell self-renewal via -catenin signaling
- (2012) T. Stoyanova et al. GENES & DEVELOPMENT
- TROP2 Correlates with Microvessel Density and Poor Prognosis in Hilar Cholangiocarcinoma
- (2012) Shanglei Ning et al. JOURNAL OF GASTROINTESTINAL SURGERY
- Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
- (2012) Sunil Verma et al. NEW ENGLAND JOURNAL OF MEDICINE
- Upregulation of Trop-2 quantitatively stimulates human cancer growth
- (2012) M Trerotola et al. ONCOGENE
- Significance of EpCAM and TROP2 expression in non-small cell lung cancer
- (2012) Min Pak et al. World Journal of Surgical Oncology
- Humanized Anti-Trop-2 IgG-SN-38 Conjugate for Effective Treatment of Diverse Epithelial Cancers: Preclinical Studies in Human Cancer Xenograft Models and Monkeys
- (2011) T. M. Cardillo et al. CLINICAL CANCER RESEARCH
- What makes a good drug target?
- (2011) Isabella Gashaw et al. DRUG DISCOVERY TODAY
- High-grade, chemotherapy-resistant primary ovarian carcinoma cell lines overexpress human trophoblast cell-surface marker (Trop-2) and are highly sensitive to immunotherapy with hRS7, a humanized monoclonal anti-Trop-2 antibody
- (2011) Joyce Varughese et al. GYNECOLOGIC ONCOLOGY
- Expression of Trop2 Cell Surface Glycoprotein in Normal and Tumor Tissues
- (2011) Lara P. Stepan et al. JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY
- Trop2 expression contributes to tumor pathogenesis by activating the ERK MAPK pathway
- (2010) Rafael Cubas et al. Molecular Cancer
- Trop2: A possible therapeutic target for late stage epithelial carcinomas
- (2009) Rafael Cubas et al. BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started